Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Brough

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Breast Cancer Research and Treatment|August 10, 2012
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibAnneleen Daemen, Denise M Wolf, James E Korkola, et al.
Nature Communications|December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Breast Cancer Research and Treatment|August 10, 2012
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibAnneleen Daemen, Denise M Wolf, James E Korkola, et al.
Nature Communications|December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Pageof 7